NCT02804399View on ClinicalTrials.gov

A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Healthy

Interventions

DRUG

PF-06463922

100 mg oral dose on day 1 in period 1 and on day 8 in period 2

DRUG

rifampin

600 mg QD from day 1 to day 12 in period 2.

Trial Locations (1)

06511

Pfizer New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY